Response to a recently published systematic review on intranasal esketamine for major depressive disorder

J Affect Disord. 2020 Aug 1;273:16-17. doi: 10.1016/j.jad.2020.04.026. Epub 2020 May 7.

Abstract

A recently published meta-analysis on the use of intranasal esketamine for the treatment of major depressive disorder included a mistake in the data analysis. This letter explains the error and offers an alternative analysis. Fortunately in this case the results are little effected.

Keywords: Depression; Esketamine; Meta-analysis.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Depressive Disorder, Major* / drug therapy
  • Depressive Disorder, Treatment-Resistant* / drug therapy
  • Double-Blind Method
  • Humans
  • Ketamine

Substances

  • Antidepressive Agents
  • Esketamine
  • Ketamine